• Overcoming Antibiotic Resistance

    May 29th, 2024TAXIS Blog

    Antibiotic resistance – or antimicrobial resistance (AMR) – has been making headlines for decades. At TAXIS Pharmaceuticals, we have been working since 2009 on the development of compounds that combat antimicrobial resistance.

  • TAXIS Publishes on Efflux Pump Inhibitors in MDPI Journal Antibiotics

    May 26th, 2022News Releases

    Efflux pumps in Gram-negative bacteria such as Pseudomonas aeruginosa provide intrinsic antimicrobial resistance by facilitating the extrusion of a wide range of antimicrobials. Approaches for combating efflux-mediated multidrug resistance involve, in part, developing indirect antimicrobial agents capable of inhibiting efflux, thus rescuing the activity of antimicrobials previously rendered inactive by efflux. Herein, TXA09155 is presented as a novel efflux pump inhibitor (EPI) formed by conformationally constraining our previously reported EPI TXA01182. TXA09155 demonstrates strong potentiation in combination with multiple antibiotics with efflux liabilities against wild-type and multidrug-resistant (MDR) P. aeruginosa.

  • cover captures the breadth and depth of modalities represented in the CARB-X portfolio of nontraditional therapeutics and preventatives and spotlights exemplar projects in the areas of protein therapeutics, potentiators, microbiome-modifying agents, bacteriophage products, anti-virulence approaches, and peptide therapeutics.

    TAXIS Pharmaceuticals appears in August special issue on Antibiotic Alternatives in ACS Infectious Diseases

    August 13th, 2021News Releases

    Efflux Pump Inhibitor (EPI) drug candidates appears in the August 13th special Antibiotic Alternatives issue of ACS Infectious Diseases. The paper titled “The CARB-X Portfolio of Nontraditional Antibacterial Products”